Clinical Trials · NCT06134271
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Jianbin Bi
- Enrollment
- 160
- Start date
- Nov 2023
- Locations
- See registry
- Primary endpoint
- Time to castration-resistant prostate cancer (CRPC)